NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option for Novartis to extend two additional years, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. The deal is worth a "few million dollars" Compugen CEO Mor Amitai told GenomeWeb.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.